TREATMENT PATTERNS AND DISEASE BURDEN IN CHINESE PATIENTS WITH WHO GRADE 2 ASTROCYTOMA AND OLIGODENDROGLIOMA: A CROSS-SECTIONAL STUDY
Author(s)
Yining Wu, Master's Candidate1, Xiaoning He, PhD1, Jiayin Zheng, PhD2, Yingying Shen, PhD Candidate1, Minglin Sun, Master3, Lan Deng, Master4, Liyun Zhong, Master4, Xiaohui Ren, PhD4, Siliang Chen, Phd5, Yanhui Liu, PhD5, Xiaopeng Guo, Phd6, Yu Wang, PhD6, Jing Wu, PhD1, Wenbin Ma, Phd6.
1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China, 2Vanke School of Public Health, Tsinghua University, Beijing, China, 3China Alliance for Rare Disease, Beijing, China, 4Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 5West China Hospital, Sichuan University, Chengdu, China, 6Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China, 2Vanke School of Public Health, Tsinghua University, Beijing, China, 3China Alliance for Rare Disease, Beijing, China, 4Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 5West China Hospital, Sichuan University, Chengdu, China, 6Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
OBJECTIVES: WHO grade 2 astrocytoma and oligodendroglioma are the most common low-grade gliomas, primarily affecting working-age adults. However, evidence on their treatment patterns and disease burden in China remains limited. This study characterized treatment patterns and disease burden, comprising economic burden and health-related quality of life (HRQoL) among Chinese patients.
METHODS: A cross-sectional online survey was conducted among patients with astrocytoma or oligodendroglioma across 27 cities in China between August and November 2025. A total of 161 patients were enrolled, with WHO grade 2 disease accounting for 56.5% (n=91), followed by grade 3 (31.1%, n=50), grade 4 (8.1%, n=13), and unclear (4.3%, n=7). Data on demographics, treatment patterns and costs were analyzed for patients with grade 2. HRQoL was assessed using the EQ-5D-5L, EORTC QLQ-C30 v3.0 and QLQ-BN20.
RESULTS: Among patients with WHO grade 2, the mean age was 42.9 years and 60.4% had oligodendroglioma. Surgery was received by 94.5% of patients; radiotherapy and chemotherapy each accounted for 39.6%, and concurrent chemoradiotherapy for 26.4%. As many as 54.9% of patients underwent active surveillance. The mean annual total cost per patient was CNY 81,857, with indirect costs accounting for 62.0% (CNY 50,767), followed by direct medical costs (27.0%, CNY 22,076) and direct non-medical costs (11.0%, CNY 9,015). Nearly half of patients (47.3%) required caregiver support. The mean EQ-5D-5L utility score was 0.858. The most impaired domains were social (68.3) and role (80.4) functioning on the QLQ-C30, and uncertainty about the future (25.0) on the QLQ-BN20.
CONCLUSIONS: Surgical resection is nearly universal for diagnostic and initial treatment of WHO grade 2 astrocytoma and oligodendroglioma, yet postoperative management remains limited to active surveillance and conventional chemoradiotherapy. Patients bear substantial disease burden, driven by high indirect costs and HRQoL impairments in social and role functioning.
METHODS: A cross-sectional online survey was conducted among patients with astrocytoma or oligodendroglioma across 27 cities in China between August and November 2025. A total of 161 patients were enrolled, with WHO grade 2 disease accounting for 56.5% (n=91), followed by grade 3 (31.1%, n=50), grade 4 (8.1%, n=13), and unclear (4.3%, n=7). Data on demographics, treatment patterns and costs were analyzed for patients with grade 2. HRQoL was assessed using the EQ-5D-5L, EORTC QLQ-C30 v3.0 and QLQ-BN20.
RESULTS: Among patients with WHO grade 2, the mean age was 42.9 years and 60.4% had oligodendroglioma. Surgery was received by 94.5% of patients; radiotherapy and chemotherapy each accounted for 39.6%, and concurrent chemoradiotherapy for 26.4%. As many as 54.9% of patients underwent active surveillance. The mean annual total cost per patient was CNY 81,857, with indirect costs accounting for 62.0% (CNY 50,767), followed by direct medical costs (27.0%, CNY 22,076) and direct non-medical costs (11.0%, CNY 9,015). Nearly half of patients (47.3%) required caregiver support. The mean EQ-5D-5L utility score was 0.858. The most impaired domains were social (68.3) and role (80.4) functioning on the QLQ-C30, and uncertainty about the future (25.0) on the QLQ-BN20.
CONCLUSIONS: Surgical resection is nearly universal for diagnostic and initial treatment of WHO grade 2 astrocytoma and oligodendroglioma, yet postoperative management remains limited to active surveillance and conventional chemoradiotherapy. Patients bear substantial disease burden, driven by high indirect costs and HRQoL impairments in social and role functioning.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR245
Topic
Epidemiology & Public Health, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Neurological Disorders, Oncology